Total Payments
$917,929
2024 Payments
$156,251
Companies
43
Transactions
1,896
Medicare Patients
3,496
Medicare Billing
$363,554
Payment Breakdown by Category
Other$716,686 (78.1%)
Travel$114,355 (12.5%)
Consulting$44,465 (4.8%)
Food & Beverage$41,320 (4.5%)
Research$831.60 (0.1%)
Education$271.42 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $707,986 | 320 | 77.1% |
| Travel and Lodging | $114,355 | 359 | 12.5% |
| Consulting Fee | $44,465 | 25 | 4.8% |
| Food and Beverage | $41,320 | 1,178 | 4.5% |
| Honoraria | $8,700 | 4 | 0.9% |
| Unspecified | $831.60 | 1 | 0.1% |
| Education | $271.42 | 9 | 0.0% |
Payments by Type
General
$917,097
1,895 transactions
Research
$831.60
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $323,563 | 488 | $0 (2024) |
| GENZYME CORPORATION | $171,751 | 216 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $167,609 | 344 | $0 (2024) |
| GlaxoSmithKline, LLC. | $73,729 | 177 | $0 (2024) |
| Optinose US, Inc. | $72,074 | 120 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $41,092 | 89 | $0 (2023) |
| ALK-Abello, Inc | $22,534 | 53 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $14,258 | 47 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $11,030 | 38 | $0 (2021) |
| Merck Sharp & Dohme LLC | $6,313 | 17 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $156,251 | 208 | Regeneron Healthcare Solutions, Inc. ($42,800) |
| 2023 | $170,851 | 317 | Regeneron Healthcare Solutions, Inc. ($96,603) |
| 2022 | $150,756 | 260 | GENZYME CORPORATION ($50,160) |
| 2021 | $81,665 | 199 | Regeneron Healthcare Solutions, Inc. ($28,976) |
| 2020 | $56,402 | 173 | Regeneron Healthcare Solutions, Inc. ($22,322) |
| 2019 | $154,391 | 321 | Regeneron Healthcare Solutions, Inc. ($59,739) |
| 2018 | $108,748 | 244 | AstraZeneca Pharmaceuticals LP ($34,046) |
| 2017 | $38,864 | 174 | Boehringer Ingelheim Pharmaceuticals, Inc. ($16,280) |
All Payment Transactions
1,896 individual payment records from CMS Open Payments — Page 1 of 76
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $23.44 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $26.41 | General |
| Category: Respiratory | ||||||
| 12/10/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $33.76 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $14.55 | General |
| Category: Respiratory | ||||||
| 12/03/2024 | Optinose US, Inc. | Xhance (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,530.00 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 12/03/2024 | Optinose US, Inc. | Xhance (Drug) | Travel and Lodging | Cash or cash equivalent | $1,059.40 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 12/03/2024 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $127.11 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 12/03/2024 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | Cash or cash equivalent | $25.40 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 11/20/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $48.10 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/14/2024 | Optinose US, Inc. | Xhance (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,530.00 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 11/14/2024 | Optinose US, Inc. | Xhance (Drug) | Travel and Lodging | Cash or cash equivalent | $1,528.55 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 11/14/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,333.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/14/2024 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $127.80 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 11/14/2024 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | Cash or cash equivalent | $47.52 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 11/11/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,250.00 | General |
| Category: Respiratory | ||||||
| 11/08/2024 | CSL Behring | Haegarda (Biological) | Food and Beverage | In-kind items and services | $32.78 | General |
| Category: Immunology | ||||||
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Travel and Lodging | In-kind items and services | $787.67 | General |
| Category: Respiratory | ||||||
| 11/07/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $45.38 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/29/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,597.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/27/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $112.47 | General |
| Category: DERMATOLOGY | ||||||
| 10/26/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $1,067.40 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/26/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $42.31 | General |
| 10/26/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $6.19 | General |
| Category: Immunology | ||||||
| 10/25/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $129.73 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/24/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,333.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis | Circassia Pharmaceuticals Inc | $831.60 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 780 | 6,812 | $257,412 | $82,755 |
| 2022 | 13 | 868 | 7,422 | $288,040 | $89,992 |
| 2021 | 14 | 997 | 8,636 | $317,879 | $103,502 |
| 2020 | 12 | 851 | 8,164 | $291,713 | $87,304 |
Total Patients
3,496
Total Services
31,034
Medicare Billing
$363,554
Procedure Codes
54
All Medicare Procedures & Services
54 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 282 | 505 | $80,285 | $30,710 | 38.3% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2023 | 53 | 1,425 | $40,110 | $14,971 | 37.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 62 | 98 | $23,116 | $9,133 | 39.5% |
| 95004 | Test for allergy using allergenic extract | Office | 2023 | 53 | 3,154 | $40,099 | $7,646 | 19.1% |
| 95117 | Professional service for multiple injections of allergen | Office | 2023 | 72 | 1,001 | $26,525 | $7,415 | 28.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $8,241 | $2,765 | 33.5% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 83 | 126 | $10,008 | $2,316 | 23.1% |
| 95115 | Professional service for single injection of allergen | Office | 2023 | 30 | 356 | $8,426 | $2,306 | 27.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 27 | 27 | $7,128 | $2,013 | 28.2% |
| 31231 | Diagnostic exam of nasal passages using an endoscope | Office | 2023 | 13 | 13 | $6,237 | $1,609 | 25.8% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 29 | 31 | $2,916 | $750.88 | 25.8% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 11 | 11 | $1,389 | $365.31 | 26.3% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 11 | 11 | $1,445 | $331.04 | 22.9% |
| 95012 | Test to measure the level of nitric oxide gas | Office | 2023 | 18 | 18 | $798.00 | $222.08 | 27.8% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 13 | 13 | $689.00 | $201.92 | 29.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 253 | 447 | $80,460 | $28,230 | 35.1% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2022 | 71 | 1,590 | $50,880 | $17,407 | 34.2% |
| 95117 | Professional service for multiple injections of allergen | Office | 2022 | 99 | 1,322 | $33,050 | $9,435 | 28.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 57 | 105 | $27,930 | $9,272 | 33.2% |
| 95004 | Test for allergy using allergenic extract | Office | 2022 | 68 | 3,256 | $42,328 | $9,270 | 21.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 38 | 38 | $15,504 | $4,222 | 27.2% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 45 | 45 | $4,500 | $3,161 | 70.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 35 | 35 | $9,345 | $2,476 | 26.5% |
| 95115 | Professional service for single injection of allergen | Office | 2022 | 32 | 363 | $7,995 | $2,299 | 28.8% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 81 | 129 | $11,352 | $2,217 | 19.5% |
About Dr. Eric Schenkel, MD
Dr. Eric Schenkel, MD is a Allergy & Immunology healthcare provider based in Bethlehem, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1306958939.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Schenkel, MD has received a total of $917,929 in payments from pharmaceutical and medical device companies, with $156,251 received in 2024. These payments were reported across 1,896 transactions from 43 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($707,986).
As a Medicare-enrolled provider, Schenkel has provided services to 3,496 Medicare beneficiaries, totaling 31,034 services with total Medicare billing of $363,554. Data is available for 4 years (2020–2023), covering 54 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy & Immunology
- Location Bethlehem, PA
- Active Since 08/31/2006
- Last Updated 04/06/2017
- Taxonomy Code 207K00000X
- Entity Type Individual
- NPI Number 1306958939
Products in Payments
- DUPIXENT (Biological) $416,661
- FASENRA (Drug) $73,758
- NUCALA (Biological) $73,249
- Xhance (Drug) $72,074
- DUPIXENT DUPILUMAB INJECTION (Biological) $43,686
- TEZSPIRE (Biological) $40,864
- AIRSUPRA (Drug) $29,786
- DUPIXENT (Drug) $29,393
- Odactra (Drug) $21,505
- SPIRIVA RESPIMAT (Drug) $21,310
- CINRYZE (Drug) $13,414
- FASENRA (Biological) $9,908
- RUCONEST (Biological) $4,406
- AIRDUO (Drug) $4,338
- QVAR (Drug) $3,431
- ATOPIC DERMATITIS - DISEASE (Drug) $3,082
- NO PRODUCT DISCUSSED (Drug) $2,435
- ArmonAir Digihaler (Drug) $1,680
- Haegarda (Biological) $1,003
- PROAIR (Drug) $759.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.